First Antibody Generated from MorphoSys's HuCAL Library Technology to Receive Marketing Approval
PLANEGG, MUNICH, GERMANY / ACCESSWIRE / July 13, 2017 / MorphoSys AG (FSE: MOR; XETRA: MOR, Prime Standard Segment, TecDAX; OTC
PINK: MPSYY) announced today that its licensee, Janssen Biotech, Inc. ("Janssen"), has reported that the U.S. Food and Drug
Administration ("FDA") has approved Tremfya™ (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis.
Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary
HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval.
Financial details were not disclosed.
Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, said, "It is a very exciting day for all of us at MorphoSys to have
the first antibody generated from our proprietary HuCAL antibody technology receive marketing approval. We are grateful to Janssen
for their development efforts and look forward to the launch of Tremfya. Plaque psoriasis is a chronic disease affecting millions
of people worldwide, and it is fantastic news that this therapy will now be made available to patients living with moderate to
severe disease. We are also very pleased that Janssen is pursuing the development of Tremfya in several additional
indications."
Dr. Moroney continued, "With more than 100 MorphoSys compounds currently in development, we look forward to advancing novel
antibodies in a wide variety of serious diseases where we see a strong need for alternative treatment options."
Further information can be found in the press release issued by Janssen on July 13, 2017.
MorphoSys will provide information on on financial guidance at a later date.
About Psoriasis
Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterized by
raised, inflamed, scaly, red lesions, or plaques, which can cause itching and physical pain. It is estimated that as many as 125
million people worldwide have psoriasis, including 14 million Europeans, and approximately 20% of people affected have cases that
are considered moderate to severe.
About MorphoSys:
MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the
field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of
biopharmaceuticals in the biotechnology industry. Based on its proprietary technology platforms, MorphoSys, together with its
partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical
development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates,
mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new
drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based
payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about
MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R),
Slonomics(R), Lanthio Pharma(R), and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya™ is a trademark of Janssen Biotech, Inc.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties.
Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG Anke Linnartz Head of Corporate Communications & IR
Jochen Orlowski Associate Director Corporate Communications & IR
Alexandra Goller Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com
SOURCE: MorphoSys AG via the EQS Newswire distribution service including Press Releases and Regulatory
Announcements
